# Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612

> **NCT00427908** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 613 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)
- **BIOLOGICAL:** Mencevax™ ACWY
- **BIOLOGICAL:** Meningitec™

## Key facts

- **NCT ID:** NCT00427908
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-07
- **Primary completion:** 2007-12-03
- **Final completion:** 2007-12-03
- **Target enrollment:** 613 (ACTUAL)
- **Last updated:** 2018-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427908, "Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00427908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*